BioLineRx Ltd. In-Licenses BL-3010 From Gevys Pharmaceuticals For The Treatment Of Pain And Plans To Initiate Phase I/II Trial

Published: May 25, 2006

BioLineRx, Ltd., Israel's leading drug development company, today announced that it has signed an exclusive worldwide licensing agreement with Gevys Pharmaceuticals Ltd. for the development and commercialization of BL-3010, a novel approach for the treatment of acute and chronic pain. Gevys's patented technology utilizes a combination of approved drugs to dramatically increase the potency of micro-doses of classical pain medications. The result is that BL-3010 will deliver effective pain relief with significant reductions in toxicity and side effects.

Back to news